Table II.
Treatment data.
| Dose administered (IU) | Dose administered (IU/kg) | ||||
|---|---|---|---|---|---|
| Number of patients | Mean (SD) | Median (range) | Mean (SD) | Median (range) | |
| Overall population | 135 | 2,566.7 (1,272.3) | 2,000 (250–7,000) | 44.0 (14.6) | 40 (20.0–83.3) |
| Population =15 years | 47 | 1,702.1 (1,168.7) | 1,250 (250–6,000) | 47.6 (16.9) | 44.4 (20.4–83.3) |
| Population >15 years | 88 | 3,028.4 (1,073.1) | 3,000 (1,500–7,000) | 42.1 (12.9) | 40.0 (20.2–72.7) |
| Prophylaxis | 57 | 2,368.4 (1,216.6) | 2,000 (500–6,000) | 44.5 (14.9) | 40 (20.0–80.0) |
| On-demand | 74 | 2,729.7 (1,318.8) | 3,000 (250–7,000) | 43.3 (14.7) | 40 (20.3–83.3) |
| HIV+ | 19 | 2,737.8 (991.2) | 2,500 (1,000–5,000) | 39.9 (11.3) | 40 (20.4–63.6) |
| HIV− | 110 | 2,540.9 (1,330.9) | 2,000 (250–7,000) | 44.5 (15.1) | 40 (20.3–83.3) |
| HCV+ | 51 | 3,019.6 (932.5) | 3,000 (1,000–6,000) | 42.2 (11.9) | 40 (20.4–83.3) |
| HCV− | 65 | 2,407.7 (1,515.2) | 2,000 (250–7,000) | 47.8 (16.1) | 47.1 (20.3–80.0) |
| Co-infected | 17 | 2,823.5 (1,014.6) | 3,000 (1,000–5,000) | 41.1 (11.3) | 40 (20.4–63.6) |